<?xml version='1.0' encoding='utf-8'?>
<document id="29226313"><sentence text="Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development."><entity charOffset="70-79" id="DDI-PubMed.29226313.s1.e0" text="Alectinib" /></sentence><sentence text="Alectinib is a selective anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of ALK-positive non-small cell lung cancer"><entity charOffset="0-9" id="DDI-PubMed.29226313.s2.e0" text="Alectinib" /></sentence><sentence text=" Alectinib and its major active metabolite M4 exhibited drug-drug interaction (DDI) potential through cytochrome P450 (CYP) enzymes CYP3A4 and CYP2C8 in vitro" /><sentence text=" Clinical relevance of the DDI risk was investigated as part of a rapid development program to fulfill the breakthrough therapy designation" /><sentence text=" Therefore, a strategy with a combination of physiologically based pharmacokinetic (PBPK) modeling and limited clinical trials focused on generating informative data for modeling was made to ensure extrapolation ability of DDI risk" /><sentence text=" The PBPK modeling has provided mechanistic insight into the low victim DDI risk of alectinib through CYP3A4 by a novel two-dimensional analysis for fmCYP3A4 and FG , and demonstrated negligible CYPs 2C8 and 3A4 enzyme-modulating effects at clinically relevant exposure" /><sentence text=" This work supports that alectinib can be prescribed without dose adjustment for CYP-mediated DDI liabilities"><entity charOffset="25-34" id="DDI-PubMed.29226313.s7.e0" text="alectinib" /></sentence><sentence text="" /></document>